US › Healthcare

Compugen (CGEN)

US · Healthcare · Biotechnology

$2.46+2.07%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$2.6M

Revenue YoY

+107.0%

Net profit

$-7.0M

EPS

$-0.07

EPS estimate

$-0.07

Net margin

-269.3%

EPS came in at -0.07 against a street estimate of -0.07 — a beat of 0.0%.

Key statistics

Market cap

$234.0M

P/E

6.3

Forward P/E

12.4

P/B

2.62

Book value

$0.94

EPS (TTM)

$0.39

52-week high

$3.23

52-week low

$1.29

50-day MA

$2.44

200-day MA

$2.19

Beta

2.79

Analyst view

Analysts rate Compugen a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $4.60.

Shareholding

Insiders

2.10%

Institutions

15.21%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Compugen — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.